HALO HALOZYME THERAPEUTICS, INC. Insider Trading

HALO CEO Helen Torley sells 50,000 shares for $3.4M under pre-arranged 10b5-1 plan on 2026-06-01/03

Helen Torley (President and CEO) executed 9 separate sales totaling 50,000 shares for $3,370,008.22 across three trading days (June 1–3, 2026) at an average price of $67.40 per share. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-21, meaning it was scheduled and not a discretionary decision by the executive. Post-transaction, Torley retains 767,780 non-derivative shares along with derivative holdings of 45,769 option shares, reducing her non-derivative position by 6.1%. The sale follows a pattern of recurring sales; Torley has sold at this ticker on five prior occasions (2026-05-12 and 2026-05-13), all of which showed negative 30- and 90-day returns ranging from -2.7% to -7.1%. Her cross-ticker track record of 20 prior sells shows an average 90-day return of -2.1%, suggesting her sales have historically preceded modest price declines. With HALO trading at $69.82 and the company reporting strong fundamentals—$376.7M in quarterly revenue, $150.0M net income, and 37.6% annual revenue growth—the scheduled nature of this sale limits its interpretive value as a discretionary signal.

CEO Helen Torley exercised options and immediately sold all gains, offsetting 50K shares acquired with 50K disposed—a neutral stake pattern that masks heavy profit-taking.

Helen Torley, President and CEO of HaloZyme, executed a high-volume trading sequence over three days: exercising 50,000 shares at a fixed price and simultaneously selling the same number of shares across twelve separate transactions at prices ranging significantly higher. This is a mechanically neutral net position—her direct stake remained essentially flat at 767,780 shares—but the transaction pattern itself reveals important context. Torley is a serial seller with 104 open-market sales across all her holdings in the trailing 36 months (12 at HaloZyme in this filing alone), and her five prior HaloZyme sales showed mixed timing: three were well-timed exits where the stock subsequently fell, but two were poorly timed as the stock rallied afterward. Over the longer 90-day horizon, all five prior HaloZyme exits proved poorly timed, as the stock gained in every instance. The current exercise-and-sell pattern happens while the stock trades well below its 52-week high and the company shows strong fundamentals—profitable with accelerating revenue growth and a reasonable valuation multiple. Torley's willingness to immediately liquidate every exercised share, combined with her exclusively sell-focused filing history and the mixed historical accuracy of her HaloZyme exits, does not convey insider conviction in the stock's near-term trajectory.

CEO Torley Helen sells 10,000 HALO shares across 2 trades for $634,981.60 ($63.50 avg); stock down 21.7% from 52-week high.

Torley Helen, President and CEO, executed 2 separate sales on 2026-04-06, totaling 10,000 shares for $634,981.60 at a blended average price of $63.50. The sale reduced her holdings from 777.8K to 767.8K shares (-1.3%). The current price is $63.60, slightly above the transaction price, and the stock is -21.7% from its 52-week high of $81.23, down 5.6% over 30 days and 15.3% over 90 days. The company shows strong fundamentals—annual revenue growth of +37.6%, a P/E of 16.02, and net income of $175.2M—which does not signal operational distress. Notably, Helen has executed 4 prior sales at HALO in the preceding five days (2026-04-01 and 2026-04-02), with the most recent measurable outcome (2026-03-04 sale) showing -9.1% return at 30 days. The pattern of frequent consecutive sales warrants examination against any scheduled plan or non-discretionary context; without explicit disclosure, the rapid cadence and recent price weakness merit investor attention.

HALO CEO Torley Helen sells 40,000 shares for $2.6M under pre-arranged 10b5-1 plan (adopted 2025-03-21)

Helen Torley, President and CEO of HaloZyme, executed 4 separate sales totaling 40,000 shares for $2,592,236.80 at a blended average price of $64.81 across April 1-2, 2026. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-21, meaning the sales were scheduled and not discretionary. Post-transaction, Torley retains 767,780 shares, representing a 5.0% reduction from prior holdings of 807,780 shares. The scheduled nature of this transaction precludes any inference about current conviction or market timing—10b5-1 plans are established on fixed schedules and executed mechanically regardless of near-term price movement.

HALO COO Cortney Caudill sells 28.9K shares for $2.0M across 3 transactions; retains 7.1K shares (80.4% position reduction)

Cortney Caudill, SVP and Chief Operating Officer of HaloZyme Therapeutics, executed 3 separate sales on 2026-03-09 and 2026-03-10, selling 28,857 shares (28.9K shares) for a combined $1,955,159.58 ($2.0M) at prices between $67.64 and $68.25 per share. This represents an 80.4% reduction in her holdings, from 35,912 shares pre-transaction to 7,055 shares post-transaction. The sales occurred near the 52-week high of $81.23, with the current price at $67.81 reflecting a -16.5% pullback from that peak over the past 30 days. HaloZyme's fundamentals remain strong, with annual revenue growth of +37.6%, net income of $175,225,000.00, and a P/E of 17.08. The substantial reduction in an executive's equity position merits scrutiny, particularly given the scope of the divestiture and the COO's operational visibility into company performance.

CEO Helen Torley sold 50,000 shares ($3.5M) across 7 transactions Mar 2–4 at blended avg $69.52, reducing stake 6.1% to 767.8K shares post-sale.

Torley Helen, President and CEO of HaloZyme Therapeutics, executed 7 separate open-market sales totaling 50,000 shares for $3,476,156.80 across March 2–4, 2026, at an average price of $69.52 per share. The sale reduces her holdings from 817.8K to 767.8K shares, a -6.1% reduction in position size. The current price of $70.02 sits -13.8% below the 52-week high of $81.23, and the stock has declined -6.0% over the prior 30 days while rising +11.2% over 90 days. Her cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 23.08% and an average 90-day return of +9.0%, suggesting her prior sells have not consistently preceded declines; notably, her five most recent trades at HALO itself (all sales between Feb 3–5, 2026) lack measurable 90-day outcomes. With the company reporting strong fundamentals—$354.3M quarterly revenue, $175.2M net income, and +37.6% annual revenue growth—and trading at a P/E of 17.64 against an $8.3B market cap, the sale occurs in a context of solid operational performance and recent valuation pullback, not operational distress.

HALO CEO Torley Helen sold 50,000 shares for $3.9M across 7 transactions (Feb 3–5); holds 708.7K shares post-sale.

Torley Helen, the President and CEO of HaLozyme, executed 7 separate sales totaling 50,000 shares for $3,853,503.25 between February 3 and 5, 2026, at prices ranging from $74.88 to $78.94 with a blended average of $77.07. The sale reduced her holdings by 6.6%, from 758.7K to 708.7K shares, while the stock currently trades at $78.42—just 1.9% above the execution prices. The timing context is noteworthy: across his cross-ticker track record of 20 prior sales, the average 90-day return has been -5.1% with a 90-day well-timed rate of 100%, but his 5 prior sales at HALO specifically (all in November and December 2025) showed mixed 30-day results (-1.8% to -11.4%) with no 90-day outcomes yet measurable. The company's fundamentals remain solid—annual revenue growth of +22.4%, a P/E of 15.50, and net income of $175,225,000.00 on quarterly revenue of $354,264,000.00—suggesting the sale reflects position management rather than company deterioration.

HALO CEO Torley Helen sold 16,569 shares for $1,141,924.75 on 2025-12-01 at blended avg $68.92

Torley Helen, President and CEO of HaloZyme Therapeutics, executed 4 separate sales totaling 16,569 shares for $1,141,924.75 ($1.1M) on 2025-12-01, reducing holdings from 725,288 shares to 708,719 shares (-2.3%). The sales occurred at prices ranging from $68.51 to $71.60, with a blended average of $68.92, at a point when the stock was -13.0% from its 52-week high of $78.28 and trading at $68.10 currently (+4.5% over 30 days, -7.1% over 90 days). Across the insider's cross-ticker track record of 20 prior sells, the average 30-day return has been -9.2%, indicating a historical pattern of selling into periods of relative underperformance. HaloZyme's fundamentals remain solid with annual revenue growth of +22.4%, a P/E of 13.46, and recent quarterly revenue of $354.3M with net income of $175.2M, providing context that this sale occurs within a company showing strong financial performance.

HALO CEO Torley Helen sold 60,000 shares for $4.2M across Nov 10-12; part of pre-arranged 10b5-1 plan adopted Mar 21.

Torley Helen, HALO's President and CEO, executed 8 separate sales totaling 60,000 shares for $4,167,929.57 at a blended average price of $69.47 per share across three trading days (November 10–12, 2025). This reduction represents a 7.6% decrease in her pre-transaction holdings of 793.7K shares, leaving her with 733.7K shares post-transaction. Critically, this transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-21, meaning the sales were scheduled in advance rather than discretionary decisions made in response to current market conditions. The multi-day execution across a price range of $67.89 to $71.67 reflects the systematic nature of the plan's schedule, not active trading judgment on her part.

CEO Torley Helen sells 60,000 HALO shares across 11 transactions for $4.3M at blended avg $71.86

Torley Helen, President and CEO of HaloZyme Therapeutics, executed 11 separate sales totaling 60,000 shares for $4,311,745.13 on 2025-10-01 through 2025-10-03, reducing her holdings by 7.6% from 793.7K to 733.7K shares. The blended average sale price of $71.86 sits 4.2% above the current price of $68.98, indicating the sales occurred at a near-recent high despite the stock being 11.9% down from its 52-week high of $78.28. HaloZyme's fundamentals remain solid with annual revenue growth of +22.4%, net income of $165.2M on quarterly revenue of $325.7M, and a P/E of 14.49, suggesting the company is operationally sound. However, the magnitude of the CEO's disposal—$4.3M in concentrated selling across just three trading days—warrants observation, particularly given the recent 30-day and 90-day price weakness (-7.8% and +27.7% respectively) and prior same-ticker sales in early September that showed negative 30-day returns of -7.1% and -7.6%.